Healthcare Stocks Under Scrutiny: Opportunities Amid Declines

This chapter explores the recent decline in healthcare stocks as the new year approaches, with a particular focus on Eli Lilly's performance and the political risks surrounding it. It also examines Vertex Pharmaceuticals' transformation and advancements in non-addictive painkillers.